B
Bull
Bull · 25%CNTB
$1.88
Szenariopreis
$2.230
-0.049 (-2.19%)Zum Schluss
Loading chart…
- High
- 2.320
- Open
- 2.320
- VWAP
- 2.25
- Vol
- 340.77K
- Mkt Cap
- 70.53M
- Low
- 2.200
- Amount
- 766.72K
- EV/EBITDA, TTM
- -0.21
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
AI analysis of Connect Biopharma Holdings Ltd (CNTB)
buyConnect Biopharma Holdings Ltd is a good buy right now due to its upcoming Phase 2 trial results for Rademikibart, expected to be a significant catalyst for the stock. The current price is $2.23, and analysts have set price targets of $6 to $8, indicating substantial upside potential of 169% to 259%. Additionally, the stock has a forward P/E ratio of 0.7669, suggesting it is undervalued compared to its future earnings potential. However, the main risk is the company's negative net income, which was -$17,284,000 in the latest quarter, indicating ongoing financial challenges that investors should monitor closely.
Bewertungskennzahlen
The current forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB) is 0.77, compared to its 5-year average forward P/E of -2.42.
Alphio AI Price Scenarios for CNTB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CNTB
Event-Zeitleiste
News
2.007-10NASDAQ.COMVirax Biolabs Partners with Fosun Diagnostics, Shares Surge
6.006-26CNBCMajor Wall Street Rating Changes on Friday
4.506-03NASDAQ.COMBiotech Stocks Pre-Market Trading Insights
9.004-24NASDAQ.COMConnect Biopharma Initiates Phase 2 Trial for Rademikibart in Asthma and COPD
8.504-03NASDAQ.COMBiotech Landscape Update: Regulatory Approvals and Acquisitions
CNTB FAQ — answered by Alphio AI
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Connect Biopharma Holdings Ltd is a good buy right now due to its upcoming Phase 2 trial results for Rademikibart, expected to be a significant catalyst for the stock. The current price is $2.23, and analysts have set price targets of $6 to $8, indicating substantial upside potential of 169% to 259%. Additionally, the stock has a forward P/E ratio of 0.7669, suggesting it is undervalued compared to its future earnings potential. However, the main risk is the company's negative net income, which was -$17,284,000 in the latest quarter, indicating ongoing financial challenges that investors should monitor closely.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.